CAS 83915-83-7
:Lisinopril dihydrate
Description:
Lisinopril dihydrate is an angiotensin-converting enzyme (ACE) inhibitor primarily used in the treatment of hypertension and heart failure. It is a white to off-white crystalline powder that is soluble in water, which facilitates its absorption in the body. The chemical formula for lisinopril dihydrate reflects its dihydrate form, indicating the presence of two water molecules associated with each lisinopril molecule. This compound works by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Lisinopril dihydrate is typically administered orally and is known for its long half-life, allowing for once-daily dosing. Common side effects may include dizziness, headache, and gastrointestinal disturbances, while serious adverse effects can involve renal impairment and hyperkalemia. As with any medication, it is essential to monitor patients for potential interactions with other drugs and underlying health conditions. Overall, lisinopril dihydrate is a widely used and effective medication in managing cardiovascular diseases.
Formula:C21H31N3O5·2H2O
InChI:InChI=1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1
InChI key:InChIKey=CZRQXSDBMCMPNJ-ZUIPZQNBSA-N
SMILES:C([C@@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)CCCCN)(=O)N2[C@H](C(O)=O)CCC2.O
Synonyms:- N~2~-(1-carboxy-3-phenylpropyl)-L-lysyl-L-proline dihydrate
- N-[2-[4-[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]5-methylpyrazinecarboxamide dihydrate
- N~2~-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline dihydrate
- L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, dihydrate
- Lisinopril dihydrate
- L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2)
- L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, dihydrate, (S)-
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 18 products.
Lisinopril Dihydrate
CAS:Formula:C21H31O5N3·2H2OPurity:>98.0%(T)Color and Shape:White to Almost white powder to crystalMolecular weight:441.53LISINOPRIL FOR SYSTEM SUITABILITY A CRS
CAS:<p>LISINOPRIL FOR SYSTEM SUITABILITY A CRS</p>Color and Shape:PowderLISINOPRIL DIHYDRATE CRS
CAS:<p>LISINOPRIL DIHYDRATE CRS</p>Formula:C21H35N3O7Color and Shape:PowderMolecular weight:441.5185Lisinopril dihydrate
CAS:Lisinopril dihydrateFormula:C21H31N3O5Purity:91.5%Color and Shape:WhiteMolecular weight:405.22637Lisinopril
CAS:<p>Cardiovascular drugs, not elsewhere specified or includ</p>Formula:C21H31N3O5·2H2OColor and Shape:White Off-White PowderMolecular weight:405.22637Lisinopril dihydrate
CAS:<p>Lisinopril dihydrate （MK-521) is an orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.</p>Formula:C21H35N3O7Purity:98.83% - 99.22%Color and Shape:White To Off-White Crystalline PowderMolecular weight:441.52L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2)
CAS:Formula:C21H35N3O7Purity:99%Color and Shape:SolidMolecular weight:441.5185Lisinopril
CAS:Formula:C21H31O5N3·2H2OPurity:(Titration) 98.0 - 102.0 % (anhydrous basis)Color and Shape:White to almost white crystalline powderMolecular weight:441.52Lisinopril Dihydrate
CAS:Controlled ProductFormula:C21H31N3O5H2OColor and Shape:NeatMolecular weight:441.52Lisinopril dihydrate
CAS:Controlled ProductFormula:C21H31N3O5H2OColor and Shape:NeatMolecular weight:441.52(S)-Lisinopril Dihydrate
CAS:<p>Stability Hygroscopic<br>Applications An orally active angiotensin-converting enzyme (ACE) inhibitor. S,S,S-Isomer of Lisinopril.<br>References Goa, K.L., et al.: Drugs, 52, 564 (1996), Chaturvedi, N., et al.: Lancet, 351, 28 (1998)<br></p>Formula:C21H31N3O5·2H2OColor and Shape:WhiteMolecular weight:441.522-Deoxy-3,4,6-tri-O-pivaloyl-D-glucopyranosyl azide
CAS:<p>2-Deoxy-3,4,6-tri-O-pivaloyl-D-glucopyranosyl azide is a drug that regulates the blood pressure. It is an oral hypoglycaemic agent that has been shown to lower blood sugar levels in patients with type 2 diabetes mellitus. The drug is metabolized in the liver by cytochrome p450 enzymes and can cause interactions with drugs such as lisinopril, which are metabolized by these enzymes. 2DGPA has been shown to be effective at lowering blood pressure in a low-dose group of patients with essential hypertension. The signal peptide sequence was detected in the protein sequencing of a biological sample from rats treated with 2DGPA. This drug also reduces natriuretic peptide levels and has a rate constant of 4s−1M−1s−1.</p>Formula:C21H35N3O7Purity:Min. 95%Molecular weight:441.53 g/mol
![L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA003RAL.jpg&w=3840&q=75)
